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A Case of Locally Advanced Well-Differentiated Fetal Adenocarcinoma 
of the Lung Treated with Concurrent Chemoradiation Therapy
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Fetal adenocarcinoma is a rare adenocarcinoma subtype of pulmonary blastoma. A 48-year-old male patient is 
being referred to our hospital due to progressive dyspnea. A chest X-ray showed a lung mass of unknown origin 
that was obstructing the right main bronchus. After relieving the airway obstruction with stent insertion via 
bronchoscopy, a diagnosis of fetal adenocarcinoma is being confirmed through thoracoscopic biopsy. Due to the 
locally advanced state of the lung cancer, it seemed to be inoperable, and concurrent chemo-radiation therapy 
was being administered with docetaxel. The stent was removed after improvements in the airway obstruction 
followed by a lung mass shrinkage. Comparing to other contexts which describe fetal adenocarcinoma as lower 
grade malignancy with low-associated mortality, herein, we describe a case of locally-advanced fetal adeno-
carcinoma (T4N3M0). This is the first documented case being treated with concurrent chemoradiation therapy. 
The followed-up image studies represent a partial response and the patient is currently under further observations. 
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Introduction
  Fetal adenocarcinoma is a very rare subtype of malig-
nant lung cancer. It was first described by Kradin et al.1 
as one subtype of pulmonary blastoma resembling the 
epithelial component of the fetal lung without a sarcom-
atous component. The updated World Health Organiza-
tion (WHO) classification lists four rare variants of in-
vasive adenocarcinoma of the lung: invasive mucinous 
adenocarcinoma (formerly known as mucinous bron-
chioloalveolar carcinoma), colloid adenocarcinoma, fe-
tal adenocarcinoma, and enteric adenocarcinoma2. Al-
though an estimate of the incidence of fetal ad-
enocarcinoma in Korea is unavailable, it is reported to 
be the cause of approximately 0.1% of all primary lung 
cancers2. Moreover, most of the reported cases in Korea 
were diagnosed in early stages, which enabled com-
plete resection of the tumor3,4. 
  Histologically, fetal adenocarcinoma is generally well- 
differentiated (low grade) and consists of columnar, gly-
cogen-rich cells growing in squamoid morules2. It is a 
low-grade malignancy and mortality is only 15%5. 
Although most fetal adenocarcinomas reported to date 
were operable2,6,7, we describe a case of inoperable ad-
vanced fetal adenocarcinoma extending to the proximal 
airway causing dyspnea and multiple lymph node meta-
stasis. We treated this case with endobronchial stent in-
sertion via an endoscopic procedure followed by con-
current chemoradiation therapy, which was successful 
in improving the patient's symptoms.
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Figure 1. (A) Chest X-ray 
showed a large mass in 
the right paratracheal area,
causing tracheal deviations
to the left, with mild bron-
chopneumonia in the right 
lower lobe. (B) Three-mon-
th followed-up chest X-ray 
scans indicated that the 
airway obstruction and tra-
cheal deviation had been 
improved.
Figure 2. (A) Computed tomography (CT) scans revealed an approximately 7.7×6.4 cm lobulated, heterogeneous, en-
hancing mass abutting the trachea, carina, and both main bronchi. (B) One-month followed-up CT showed that the 
size of the mass in the right paratracheal area had decreased (5.8 cm decreased to 4.6 cm), indicating a stable disease.
Case Report
  A 48-year-old man was referred to our hospital due 
to a lung mass of unknown origin. The patient had a 
60 pack-year smoking history. Prior to admission, the 
patient visited an outside hospital with a one-month his-
tory of dyspnea, cough and sputum. Chest imaging 
studies demonstrated a lung mass (initial size, 7.7×6.4 
cm) at the right mediastinal border with deviation of the 
trachea. After placing an endobronchial stent in the left 
main bronchus from the carina, the patient was trans-
ferred to our hospital.
  Chest X-ray (Figure 1A) showed a large mass in the 
right paratracheal area, causing tracheal deviation to the 
left with mild bronchopneumonia in the right lower 
lobe. The stent in the left main bronchus remained 
patent. Computed tomography (CT) revealed a 7.7×6.4 
cm lobulated, heterogeneous enhancing mass abutting 
the trachea, carina, and both main bronchi, as well as 
multiple enlarged lymph nodes in the subclavian, right 
hilar, subcarinal, upper and lower paratracheal areas 
(Figure 2A). A metallic stent was placed in the left main 
bronchus and irregular narrowing of the right main 
bronchial wall was also observed. Flexible broncho-
scopy (FBS) showed the placement of a stent from the 
carina to the left main bronchus, extending to the left 
second carina (Figure 3A). The left upper and lower 
bronchi appeared normal. A white fungating mass ob-
structing the right main bronchus and a pin- point open-
ing due to a mass-like lesion were detected.
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Figure 4. The mass was 
composed of numerous 
glands showing endome-
trioid morphology, occa-
sional squamoid morules, 
and relatively clear cyto-
plasm (H&E stain; A, ×100;
B–D, ×400).
Figure 3. (A) Flexible bron-
choscopy allowed for the 
placement of a stent from 
the carina to the left main 
bronchus, extending to the
second left carina. (B) 
Three-month followed-up 
flexible bronchoscopy show-
ed relief of the airway ob-
struction of both the right 
and left main bronchi, 
which improved the ease 
of passing the scope.
  Thoracoscopic biopsy of the mediastinal lymph node 
was performed. Gross examination revealed a single, 2 
cm, white, well-defined mass that bled easily. Histo-
pathologically, the mass was composed of numerous 
glands showing an endometrioid morphology, occa-
sional squamoid morules (×400), and relatively clear 
cytoplasm (Figure 4). Based on these histopathological 
findings, we finalized the diagnosis as fetal adeno-
carcinoma.
  Due to the locally advanced state of the lung cancer 
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in this case, concurrent chemoradiation therapy (Tomo-
Helical; 5,500 cGy) was administered. Treatment was 
comprised of 25 mg/m2 docetaxel weekly for six weeks 
with concomitant radiation therapy; the patient com-
pleted the planned treatment regimen. Repeat CT per-
formed at a 1-month follow-up visit (Figure 2B) showed 
the mass in the right paratracheal area had decreased 
in size (5.8 cm decreased to 4.6 cm), indicating a stable 
disease. Additional follow-up chest CT and FBS were 
scheduled at 3-month intervals. On follow-up studies at 
4 months, positron emission tomography-CT showed 
significantly decreased size and activity (5.5×4.6 cm to 
4.5×3.4 cm) of the mediastinal mass, which was con-
sidered a favorable response to the treatment, and no 
other newly developed hypermetabolic foci to suggest 
distant metastasis were seen. Bronchoscopy (Figure 3B) 
showed relief of the airway obstruction of the right and 
left main bronchi, with increased ease of passing the 
scope. Compared with the previous chest X-ray (Figure 
1A), the airway obstruction and tracheal deviation were 
improved (Figure 1B). We were able to remove the 
stent from the left main bronchus. Previous symptoms 
of dyspnea and cough were also improved. A further 
partial response was noted on the 7-month follow-up 
studies, and another CT follow-up is planned in 3 
months.
Discussion
  Fetal adenocarcinoma was formerly classified as a 
subtype of pulmonary blastoma termed well-differen-
tiated fetal adenocarcinoma (WDFA)6. Because WDFA 
is characterized by a monophasic pattern consisting of 
an epithelial component alone, distinct from other pul-
monary blastoma subtypes, the WHO in 1999 removed 
WDFA tumors from the pulmonary blastoma category 
and classified them as a variant of adenocarcinoma7. 
  Our understanding of fetal adenocarcinoma is derived 
from case reports or small case series. It is estimated 
that approximately 0.1% of lung neoplasms are fetal 
adenocarcinomas. It is generally found in young pa-
tients with a unimodal age peak in the third decade, 
has a slight female predominance, and is most com-
monly early stage disease at diagnosis with no lymph 
node involvement. It is generally treated and frequently 
cured by surgical resection, and has better survival com-
pared with similarly staged and treated adenocarcinoma 
of the lung2,7. According to a study of 25 cases of fetal 
adenocarcinoma by Sato et al.7, cases in which the tu-
mor was detected on a chest radiograph as part of rou-
tine health maintenance accounted for 76% of the total. 
The tumor size at resection was comparatively small, 
with a median size of 3.5 cm (range, 1.4–12.0 cm). The 
tumors tended to be localized in the right lung, espe-
cially in the upper lobe. Among the 24 cases in which 
the pathological stage was reported, there were two cas-
es with N1 lymph node metastasis at the time of re-
section, and only one had a distant metastasis to the 
eye at the time of diagnosis. There were no N2-positive 
cases, and the vast majority of cases were N0 (22 cases, 
88%)7,8. 
  Contrasting with other cases, we described a 48- 
year-old male patient with locally advanced lung cancer 
in this paper. The lung mass was found by chest imag-
ing performed due to the patient's symptoms rather than 
through routine health maintenance screening. 
Operative intervention was impossible because of the 
degree of local advancement and the presence of multi-
ple lymph node involvement and tracheal deviation.
  The standard treatment for fetal adenocarcinoma is 
surgical resection. However, there have been no estab-
lished treatment guidelines for inoperable cases up to 
this point. Van Loo et al.6 previously reported that 
among 63 cases of pulmonary blastoma, 9 were classi-
fied as WDFA. Of these nine WDFA cases, three were 
beyond T3 stage and underwent postoperative chemo-
therapy or radiation therapy. However, the benefit of 
this therapy was unclear6. In our case, after ameliorating 
the airway obstruction with stent insertion via broncho-
scopy, concurrent chemoradiation therapy (CCRT) was 
performed with docetaxel for inoperable fetal adeno-
carcinoma. A partial response was observed on fol-
low-up chest CT at 1 month and 4 months after treat-
ment, and follow-up chest CT and FBS were scheduled 
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at 3-month intervals.
  Patients with fetal adenocarcinoma tend to have a 
better prognosis than those with other types of adeno-
carcinoma. Surgical resection is the treatment of choice 
for operable cases; however, no treatment guidelines 
have been established for inoperable cases. We encoun-
tered an inoperable case of fetal adenocarcinoma of the 
lung, and a favorable response was achieved with doce-
taxel-based CCRT. Therefore, surgical resection follow-
ing tumor down-staging with neo-adjuvant chemo-
therapy or radiation therapy is one option for effective 
treatment.
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